Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (401 reviews)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

401 publications

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Selleck's Dactolisib (BEZ235) has been cited by 401 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 35(1):108940

PubMed: 33784499 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5736

PubMed: 34086347 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2778

PubMed: 34204960 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00254-3

PubMed: 34111400 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:621906

PubMed: 34124031 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:2173-2186

PubMed: 33758505 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )
Neuroscience, 2021, S0306-4522(21)00070-1

PubMed: 33577953 ( click the link to review the publication )

SLAS Technol, 2021, 24726303211008858

PubMed: 33880947 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )
Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )
Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )

Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )
Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )
Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )
J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )
J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cancers (Basel), 2017, 9(9)E125

PubMed: 28926938 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )
Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

Cancer Lett, 2016, 374(2):250-60

PubMed: 26921131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )
Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )
Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )
J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(349):ra102

PubMed: 25351247 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )
Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )
Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

J Biol Chem, 2013, 288(41):29821-35

PubMed: 23963458 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )
Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NU\BSWR6SW62aX3pZ5Jw[mmjbDDBd5NigQ>?		MVOxPEBp	NYGxbINsTE2VTx?=	Mn3FRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	M2XHVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
MCF7	NXnyd2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWmwMlAyNTFyMDFOwG0>	Mk\ROFghcA>?	NGrtbZZFVVOR	MkDjTWM2OD1yLkezJO69VQ>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5MUmwOEc,OjN6N{G5NFQ9N2F-
HCT116	M4Lve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTlTIJCOC5yMT2xNFAh\|ryP	NXjBd\|NWPDhiaB?=	MVXEUXNQ	MV\JR\|UxRTFwMU[g{txO	M{f6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA1Lz5{M{i3NVkxPDxxYU6=
U87MG	NH\QenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnTNE4xOS1zMECg{txO	NHfkTIk1QCCq	MXTEUXNQ	MW\JR\|UxRTFwM{Kg{txO	NGHJenA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3NVkxPCd-MkO4O\|E6ODR:L3G+
HBC4	NIrLfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVGyflhKOC5yMT2xNFAh\|ryP	M4jNV\|Q5KGh?		NXO5[2RZVG:pIFfJOVA:NThwNkGgUS=>	MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
BSY1	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT2RW14OC5yMT2xNFAh\|ryP	M3G1WlQ5KGh?		NEPYRmlNd2diR1m1NF0uQC52ODDN	MkH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HBC5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVy0OpppOC5yMT2xNFAh\|ryP	NHu0O5Y1QCCq		NGOxfppNd2diR1m1NF0uPy56NzDN	Ml3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MCF7	NYr5SXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTFNVZjOC5yMT2xNFAh\|ryP	M{HkXlQ5KGh?		M4i5[2xw\yCJSUWwQU05NjF4IF2=	M1exVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MDA-MB-231	M1W0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi5NE4xOS1zMECg{txO	M{TXTFQ5KGh?		MUPMc4chT0l3ME2tPE4xQSCP	Mn;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
U251	NILGNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2GzSFAvODFvMUCwJO69VQ>?	M2KxVVQ5KGh?		MXjMc4chT0l3ME2tO{43PiCP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF268	NGrpeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWSwMlAyNTFyMDFOwG0>	MYm0PEBp		MUTMc4chT0l3ME2tO{46OiCP	M3u3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF295	NG\ReGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOwMlAyNTFyMDFOwG0>	NVrX[XVyPDhiaB?=		MkDQUI9oKEeLNUC9MVgvOzFiTR?=	NFrNcmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SF539	M4L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4K1bVAvODFvMUCwJO69VQ>?	NHzWeGM1QCCq		NXnLWYh2VG:pIFfJOVA:NThwNUmgUS=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SNB75	NWThVZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjQXmcxNjBzLUGwNEDPxE1?	NHrIWmg1QCCq		MVPMc4chT0l3ME2tPE42QCCP	NFjHdIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB78	NVLvdGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnaSpoxNjBzLUGwNEDPxE1?	NVTD[25PPDhiaB?=		MUPMc4chT0l3ME2tPE43PSCP	NWrjO2ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCC2998	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3myN\|AvODFvMUCwJO69VQ>?	NYHIclZTPDhiaB?=		M1nXXmxw\yCJSUWwQU05NjB3IF2=	NFPoOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
KM12	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTZWlJIOC5yMT2xNFAh\|ryP	MX:0PEBp		NEPnT2dNd2diR1m1NF0uPy53NDDN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
HT-29	M2jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXhSnk3OC5yMT2xNFAh\|ryP	NEH1UXM1QCCq		MlfLUI9oKEeLNUC9MVcvPzViTR?=	M4HFSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCT15	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPNNE4xOS1zMECg{txO	NEPVNG81QCCq		MmDIUI9oKEeLNUC9MVgvODNiTR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
HCT116	NGHVXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFm2d4UxNjBzLUGwNEDPxE1?	NG\JRmQ1QCCq		M17YfGxw\yCJSUWwQU04NjZzIF2=	NEX0[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H23	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn3dm0zOC5yMT2xNFAh\|ryP	MmrCOFghcA>?		NGrIPWdNd2diR1m1NF0uPy54NDDN	NFS5N2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H226	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTiNE4xOS1zMECg{txO	M{H3OVQ5KGh?		MmXmUI9oKEeLNUC9MVgvPDRiTR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H522	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2CwRVAvODFvMUCwJO69VQ>?	MojoOFghcA>?		NHzacVRNd2diR1m1NF0uQC52NTDN	MoXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H438	MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOwMlAyNTFyMDFOwG0>	MUK0PEBp		MWTMc4chT0l3ME2tPE4yOSCP	MnroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
A549	M37oNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmwMlAyNTFyMDFOwG0>	NY\zSZFYPDhiaB?=		NFP3WFBNd2diR1m1NF0uQC5yNzDN	MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	NYLJVm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XHRlAvODFvMUCwJO69VQ>?	NIexfHA1QCCq		Mnj4UI9oKEeLNUC9MVcvQDBiTR?=	NV;hWZY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DMS114	NYXwRmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv1NE4xOS1zMECg{txO	NXzkToF7PDhiaB?=		MkDWUI9oKEeLNUC9MVgvOzliTR?=	NIDI[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
LOXIMVI	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HkZ\|AvODFvMUCwJO69VQ>?	NIHScnA1QCCq		MWDMc4chT0l3ME2tPE43PiCP	MmTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR3	NXy0TpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF61ZocxNjBzLUGwNEDPxE1?	NF3FOHc1QCCq		Mnv0UI9oKEeLNUC9MVgvOTdiTR?=	NYCyUXZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nCc\|AvODFvMUCwJO69VQ>?	M4faVFQ5KGh?		NGHGVIZNd2diR1m1NF0uQC53ODDN	M2LDc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR5	NYP6bINLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUiwMlAyNTFyMDFOwG0>	Mki2OFghcA>?		MVrMc4chT0l3ME2tO{42PyCP	MmHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR8	M1rOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT2eolROC5yMT2xNFAh\|ryP	M2TJdlQ5KGh?		M4nK[Wxw\yCJSUWwQU04Njh2IF2=	NFnOfm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SKOV3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LaT\|AvODFvMUCwJO69VQ>?	MnP2OFghcA>?		NYHJZXZYVG:pIFfJOVA:NThwNEGgUS=>	MlTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
RXF631L	NYnKeGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTzNE4xOS1zMECg{txO	NGHpfmQ1QCCq		NILzZmFNd2diR1m1NF0uQC5{MTDN	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
ACHN	NU\Mb2xST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYqwMlAyNTFyMDFOwG0>	NHfaOXY1QCCq		MlrkUI9oKEeLNUC9MVcvQTViTR?=	NUXl[JRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
St-4	NWPITIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXuwMlAyNTFyMDFOwG0>	NFy5ZoM1QCCq		MkTiUI9oKEeLNUC9MVcvPDdiTR?=	M2S3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN1	NHTrZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL2W5NXOC5yMT2xNFAh\|ryP	MnXBOFghcA>?		MYHMc4chT0l3ME2tPE41OSCP	NWSxO2o3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN7	NFrZXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfre2VnOC5yMT2xNFAh\|ryP	NVjHcWd2PDhiaB?=		NV\nd\|ZRVG:pIFfJOVA:NTdwNkigUS=>	Mmj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN28	NFrZO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOwMlAyNTFyMDFOwG0>	MVu0PEBp		MmLXUI9oKEeLNUC9MVcvODdiTR?=	MnrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN45	M1q2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYSwMlAyNTFyMDFOwG0>	NW\RNWVmPDhiaB?=		Mn6yUI9oKEeLNUC9MVgvOzRiTR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN74	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Pz[lAvODFvMUCwJO69VQ>?	MYq0PEBp		M1Hoemxw\yCJSUWwQU04NjR{IF2=	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DU145	M3H5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33BTlAvODFvMUCwJO69VQ>?	NHLQNWo1QCCq		M4r0S2xw\yCJSUWwQU05NjF4IF2=	NH\Jb3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
PC3	NUj2[JlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXFSZAxNjBzLUGwNEDPxE1?	Mnu0OFghcA>?		MnnrUI9oKEeLNUC9MVgvPjZiTR?=	Mkn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
Trypanosoma brucei brucei	NHnkfJdHfW6ldHnvckBCe3OjeR?=	MWiyNFAhdk1?	MVmxNkBp	NWPvdG9JTE2VTx?=	MUTE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
Trypanosoma brucei brucei	NIDZPGFHfW6ldHnvckBCe3OjeR?=		MXOxPEBp	NUS4Z\|h7TE2VTx?=	NInIW3pKdmirYnn0bY9vKG:oIILlZ4VxfG:{LX3l[IlifGWmIHXu[I9kgXSxc3nzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIITyZY5{\mW{cnnuJJVxfGGtZR?=	M3zYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
Trypanosoma brucei brucei	M4LFemZ2dmO2aX;uJGF{e2G7	MonVNlAxKG6P	NFfCTIYyOiCq	MmDESG1UVw>?	MX3F[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	M3u1d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
Trypanosoma brucei brucei	NUTpcIhMTnWwY4Tpc44hSXO\|YYm=	MVOyNFAhdk1?	M{O4T\|EzKGh?	M2n3c2ROW09?	M2X4eGVn\mWldDDvckBxcG:\|cHjheIllgWylaH;sbY5mKGyndnXs	MnzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
UM-UC-3	NFzxPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHX1dI5KSzVyPUOxOUBxVQ>?	NIXkfY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SBC-1	M{POTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPZeVljUUN3ME23OFIheE1?	MorSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MKN1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4OzT2lEPTB;Mj64JI5O	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H720	M2nFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTNwNUegcm0>	M1rqN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BFTC-909	NF3YbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j1UGlEPTB;Mz63NUBvVQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BPH-1	M1LjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG5[pFKSzVyPUSuO\|Yhdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rMXWlEPTB;NT6wPUBvVQ>?	M4fpNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
AN3-CA	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTVwNU[gcm0>	NYG4RlltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HN	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;tTWM2OD13Lkm2JI5O	MorWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC2218	NGnBRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTZwNkGgcm0>	NIT2Vpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KP-4	NULYe4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\Ve2lEPTB;NzDuUS=>	NW\kPFVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LU-139	NEG5S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TpTmlEPTB;Nz63O{BvVQ>?	NXTTco9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ETK-1	NF\nVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHCOGFsUUN3ME23Mlg5KG6P	NEjNdGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	NWjqRo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;KcVZKSzVyPUiuOFkhdk1?	MnKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MHH-PREB-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjzOFdKSzVyPUmuNVIhdk1?	NWnUUHBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DU-4475	M134UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzUcWp4UUN3ME25MlQ1KG6P	NWf1SlVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1666	NV32OWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq2TWM2OD17LkexJI5O	M2DHUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAMA-1	NVK1T3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;zTWM2OD17Lkigcm0>	M13WblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TYK-nu	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT2TWM2OD17Lkm0JI5O	Mn;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MFE-280	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTlwOUmgcm0>	NEjpWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A549	M2fncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rXV2lEPTB;MUCuNVQhdk1?	NWjSSmpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
769-P	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTtZpE3UUN3ME2xNE41PCCwTR?=	M4DFPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
L-363	MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\jVmlVUUN3ME2xNE43QSCwTR?=	NYrmd4FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES8	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFyLkmgcm0>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PA-1	NVvJPWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHITWM2OD1zMT64NkBvVQ>?	NVPOeXZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Mewo	NWnkOXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjhTWM2OD1zMT65PUBvVQ>?	NGnXWYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HSC-3	NYnGWWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF{LkKxJI5O	MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
H4	M{TWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e5fmlEPTB;MUKuOlchdk1?	M3\Kd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BB65-RCC	NEWyZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPzPJNKSzVyPUGyMlczKG6P	NFu1S\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1793	M3rhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\mT\|NDUUN3ME2xNk45OiCwTR?=	Moq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KARPAS-45	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX:zSG9zUUN3ME2xN{42OSCwTR?=	NWXRVWJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GCT	M1rtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXLSIp2UUN3ME2xN{43QCCwTR?=	M3HhS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EoL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nKR2lEPTB;MUOuPVMhdk1?	NUfR[oFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LB2241-RCC	NWnyZ3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jBSmlEPTB;MUSuNFEhdk1?	M{LYVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ES5	NIfIPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLoc2tJUUN3ME2xOE44PCCwTR?=	NYe0XXdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LOXIMVI	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTF2Lkm5JI5O	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COR-L105	NWnHZ4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjqXo1kUUN3ME2xOU4xPCCwTR?=	M1;BNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
P12-ICHIKAWA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\wRmlEPTB;MUWuNUBvVQ>?	M2HINVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHL-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnOwTWM2OD1zNT60OUBvVQ>?	NV\sT\|h5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
VMRC-RCZ	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzjTWM2OD1zNT62N{BvVQ>?	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HH	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPCTWM2OD1zNT63JI5O	Mn;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NUGC-3	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF4LkO0JI5O	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EGI-1	M1H5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrnTWM2OD1zNj60N{BvVQ>?	MljKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OS-RC-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPMTWM2OD1zNj60O{BvVQ>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-16	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;ZNmlEPTB;MUeuNVUhdk1?	NWn4eGVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H209	NHvKfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fDS2lEPTB;MUeuNlkhdk1?	NUWyRWZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
697	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT2TWM2OD1zNz60N{BvVQ>?	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-56MG	M3XOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnubZNwUUN3ME2xO{43QSCwTR?=	MkeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
VA-ES-BJ	M2HCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF5LkizJI5O	MmDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-16	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIK5ZlhKSzVyPUG4MlA1KG6P	MoLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HGC-27	M37RUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TOV2lEPTB;MUiuNFYhdk1?	MlrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES7	M1;5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\6bYdKSzVyPUG4MlA6KG6P	NInXc5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HuH-7	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDScFlmUUN3ME2xPE41KG6P	M{nzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BCPAP	M2fyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXrNJI2UUN3ME2xPE43PSCwTR?=	MnXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1710	NGX0c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF6LkeyJI5O	NUPVN\|I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
IST-MEL1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HPWGlEPTB;MUiuO\|chdk1?	NXXNcW97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF295	M{KxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIL5PGFKSzVyPUG4Mlk{KG6P	NXXDeWFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RPMI-7951	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zNWWlEPTB;MUmuNlghdk1?	M2fIcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SF126	M4H6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF7LkSxJI5O	NV[2RXJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GAMG	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTF7LkS4JI5O	Mo\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KNS-81-FD	NEOzPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknzTWM2OD1zOT61OEBvVQ>?	MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RT-112	M2DadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXOPXQxUUN3ME2xPU43PiCwTR?=	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DEL	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJyLkS5JI5O	M33DVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CGTH-W-1	NEL1bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULROWczUUN3ME2yNE43OyCwTR?=	M{LQdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HOS	M{jLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3ZXG5KSzVyPUKxMlA3KG6P	NE\CTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fJZ2lEPTB;MkGuNFghdk1?	M2r3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RXF393	NG\NcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7lWmJKSzVyPUKxMlQ2KG6P	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2030	M2LsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoewTWM2OD1{MT61NkBvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
YH-13	M2Xqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rnW2lEPTB;MkGuPFghdk1?	NEnyOHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HT-1080	NWS2SYhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n5TmlEPTB;MkGuPVMhdk1?	NVXic21tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-SNU-1	M{DSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvGTWM2OD1{MT65OUBvVQ>?	NF;GS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
G-402	NUjMN\|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf5TWM2OD1{Mj6xOkBvVQ>?	M1fMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
786-0	NYXZOFM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTuTWM2OD1{Mj6yPUBvVQ>?	NGHsPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ME-180	M3zrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnnTWM2OD1{Mj60N{BvVQ>?	NIHnWng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB69	NFLWVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnzTWM2OD1{Mj61N{BvVQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NVTLdG05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzpSlVKSzVyPUKyMlk3KG6P	MlHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TGBC1TKB	NHfBUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPhflhKSzVyPUKzMlA2KG6P	MmDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW780	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTJ\|LkGzJI5O	MnfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MG-63	NXriN2dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{SxdWlEPTB;MkOuOFUhdk1?	Ml;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BV-173	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHFfFdiUUN3ME2yN{45PyCwTR?=	NFOx[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-51	NFXkXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PE[WlEPTB;MkOuPFkhdk1?	NF7IW3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A375	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW1b\|hKSzVyPUKzMlk{KG6P	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MEL-HO	NGrBZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJ2LkC0JI5O	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EFO-27	NGG5ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnQbVB1UUN3ME2yOE4{OyCwTR?=	M{P6TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Hs-578-T	M13BWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJ2LkW4JI5O	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NBsusSR	NIriT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4m4bWlEPTB;MkSuOkBvVQ>?	NWPR[YF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CTB-1	M3XxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlm4TWM2OD1{ND62O{BvVQ>?	MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
FTC-133	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TIOmlEPTB;MkWuNUBvVQ>?	NEjuepg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MOLT-4	NFm4dXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnrbllKSzVyPUK1MlEzKG6P	NWTpTWlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HO-1-N-1	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;he2lEPTB;MkWuNVUhdk1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES3	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrtTWM2OD1{NT6yNkBvVQ>?	NX7rbmZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TI-73	NFzGSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJ3LkK4JI5O	NWG3c21SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MPP-89	NGL6fndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHpeJY{UUN3ME2yOU4{OiCwTR?=	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-150	NYHJUHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXjPHRKSzVyPUK1Mlg6KG6P	M3jXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LXF-289	NEHDUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XaXWlEPTB;Mk[uNFQhdk1?	M1zXW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-LU-1	MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrybllKSzVyPUK2MlE4KG6P	NXzPZopsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HOP-92	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ziTmlEPTB;Mk[uOFghdk1?	M1PFR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuO9	NIHn[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTETWM2OD1{Nj63OkBvVQ>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW962	MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfnOotTUUN3ME2yOk44PiCwTR?=	M{nFb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RS4-11	NYXqTXJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ4LkmxJI5O	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H292	NWq5e29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL5WpRKSzVyPUK3JI5O	MljkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTJ5LkO2JI5O	MlW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1088	M13QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnvb5JKSzVyPUK4MlI6KG6P	M1rodVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A204	NEHsW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\id3FKSzVyPUK4MlQ4KG6P	MoTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A3-KAW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHv[3lmUUN3ME2yPE43PCCwTR?=	NWruRlN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MV-4-11	NYTCVIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nDRmlEPTB;MkiuO{BvVQ>?	NF;IRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES1	NEOxZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHjTWM2OD1{OD64OEBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ONS-76	M1KyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLX[3pKSzVyPUK5MlA2KG6P	NFPUN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-263MG	NUjxSGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfCTWM2OD1{OT6zOUBvVQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U-2-OS	NFv1cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDQTWM2OD1{OT61JI5O	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
T98G	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M376TmlEPTB;MkmuPFghdk1?	M2HoSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GI-ME-N	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXET4ZKSzVyPUK5MlkyKG6P	M3W1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BHT-101	NUnhXYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3STWM2OD1\|MD6wOUBvVQ>?	NIL1Zo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NOS-1	NHjWVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoC5TWM2OD1\|MD6xNkBvVQ>?	NXyyZVZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
AsPC-1	NVnU[m9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\QU49KSzVyPUOwMlIhdk1?	NIPOcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
QIMR-WIL	NIDLZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj4TWM2OD1\|MD62JI5O	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
JVM-3	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i1e2lEPTB;M{CuPFMhdk1?	Mn7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KU-19-19	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDaXJVtUUN3ME2zNU4yOyCwTR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OVCAR-8	NHjyOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HZc2lEPTB;M{GuNlYhdk1?	NUGxdpNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BEN	NX\Kdo9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4K0[GlEPTB;M{GuOlMhdk1?	Mof2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BE-13	M2\UbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7MTWM2OD1\|MT64NkBvVQ>?	MmnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-18	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfufYFzUUN3ME2zNU45PiCwTR?=	M2OwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ECC10	NH;nWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DBbmlEPTB;M{GuPVUhdk1?	MkTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CTV-1	NVLtXFhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXEUFRKSzVyPUOyMlgzKG6P	MnPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-800	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3exb2lEPTB;M{KuPVIhdk1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A2058	NIfxNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHvXIlEUUN3ME2zN{4zPSCwTR?=	M4PvW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
VM-CUB-1	NYXzdoZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTYS2Y5UUN3ME2zN{41OyCwTR?=	MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Ca9-22	M3[wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;OTWM2OD1\|Mz61OUBvVQ>?	NEe1RYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-684	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnTRo9KSzVyPUOzMlU5KG6P	M2TkSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RPMI-8226	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHMVZdOUUN3ME2zN{45OiCwTR?=	MmH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-NEP-1	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fmNGlEPTB;M{SuNVUhdk1?	MnrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Becker	M1nUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjHdppKSzVyPUO0MlIyKG6P	MnO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H28	M33SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT0NmpYUUN3ME2zOE41PCCwTR?=	NXK1UGVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-120	M4XnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN2LkeyJI5O	M3Hj[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-157	M4i1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLDcXJFUUN3ME2zOU41OSCwTR?=	NFnX[HU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OVCAR-5	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzrOZBnUUN3ME2zOU41PyCwTR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LAMA-84	NEThcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWj0RmVuUUN3ME2zOU45PyCwTR?=	MnfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAKI-1	NW\l[2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTN4LkSzJI5O	NVzQZoJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Daoy	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn35TWM2OD1\|Nj63JI5O	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-62	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEO5c2dKSzVyPUO2Mlg3KG6P	MlTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8-MG-BA	NFrodHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvCeYlKSzVyPUO3MlI2KG6P	MojYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8505C	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTN5LkWxJI5O	NVLiOZB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LNCaP-Clone-FGC	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[3dmlEPTB;M{euOVkhdk1?	M13GfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-39	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnOWIhKSzVyPUO3Mlkhdk1?	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MN-60	NWK2[Wp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjVNG9DUUN3ME2zO{46PiCwTR?=	NHPMOHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RKO	NHfpZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTN6LkOzJI5O	M1\sN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
U251	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3z2XmlEPTB;M{iuOFMhdk1?	NG\BRYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SJSA-1	NIPidoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHiRXZrUUN3ME2zPE42PCCwTR?=	MmjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-12T	NIPNOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTUSXhyUUN3ME2zPE43KG6P	MnW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1419	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTN6LkexJI5O	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CO-314	NIH3XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW2TG1KSzVyPUO4Mlc1KG6P	M1qwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB1047-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTN6LkixJI5O	NInnUVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A101D	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmThTWM2OD1\|OD65O{BvVQ>?	NWnTe2RORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MDA-MB-175-VII	M1XocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7CTWM2OD1\|OT61NUBvVQ>?	MmTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MZ2-MEL	NHHKTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV6yZ4VrUUN3ME2zPU43PiCwTR?=	M4rrRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXtTWM2OD12MD62OEBvVQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
G-401	M4DrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTJTWM2OD12MD64NkBvVQ>?	NVTSPGpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PnR2lEPTB;NEGuNFIhdk1?	MoDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8305C	M2TabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjOTWM2OD12MT64O{BvVQ>?	Mo\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BHY	M1rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{D2cmlEPTB;NEKuO\|Ihdk1?	M1fEeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M1jqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTR\|IH7N	NEf5XmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
T-24	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPmXXkxUUN3ME20N{45OyCwTR?=	NYSzdIozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EPLC-272H	M{foPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG1c\|drUUN3ME20OE4{QSCwTR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PSN1	NH74T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTR2LkSgcm0>	NWPsbGJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2452	NHXHcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4OxfmlEPTB;NESuOVghdk1?	NH\WdIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KS-1	NIO3RpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHEbFRKSzVyPUS0MlY3KG6P	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3zTWM2OD12ND65NkBvVQ>?	M1jYdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KNS-62	NHjJOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPYUohKSzVyPUS1MlM5KG6P	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NOMO-1	NEfSSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTR3Lki3JI5O	M322SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-HEP-1	M4XM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWH0epRsUUN3ME20Ok4xPCCwTR?=	M3TxZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGR-1	NVnXTVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LFfWlEPTB;NE[uNVMhdk1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-180	NWnhT5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrEeotnUUN3ME20Ok4yPyCwTR?=	MkHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-22	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\5e4RKSzVyPUS2MlIhdk1?	MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1355	NELIXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjHZ3pzUUN3ME20Ok4{PCCwTR?=	NY\a[pAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DOHH-2	M2L1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTR4LkO3JI5O	NGLkT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A4-Fuk	NUfIcVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1OwbGlEPTB;NE[uOVIhdk1?	Mn;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PC-14	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XiVmlEPTB;NE[uOVchdk1?	M1\sfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-5	NHPxWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LDbGlEPTB;NE[uPFQhdk1?	NGfDT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LB996-RCC	M4TDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{e0TGlEPTB;NEeuNVkhdk1?	NHXiUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1623	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnGTWM2OD12Nz63OkBvVQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NWjldVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzyeYZOUUN3ME20PE4{OiCwTR?=	M4TsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LoVo	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{POSGlEPTB;NEiuOEBvVQ>?	MmT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MCF7	M1vlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHjUWkzUUN3ME20PE42QCCwTR?=	NGnx[m89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AGS	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[2e\|NKSzVyPUS4Mlc4KG6P	NF\3c\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PFSK-1	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXTUYNKSzVyPUS5MlA3KG6P	NYPEfXRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
22RV1	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1GzWGlEPTB;NEmuNFkhdk1?	M{nFNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COR-L23	M{XPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTR7LkG2JI5O	NIexfYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-283MED	M{Thb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHzUoNKSzVyPUS5MlYyKG6P	M{PyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW982	M2LISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTR7LkmxJI5O	NHPLfIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW620	NVfXWW9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrXeJR7UUN3ME21NE4{PiCwTR?=	NFPlO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-140	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vudWlEPTB;NUCuOVUhdk1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GCIY	NFLCS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vlUWlEPTB;NUCuOlchdk1?	NVPXfmNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MHH-ESS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf4O3lKSzVyPUWxMlk2KG6P	M4ruZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
D-423MG	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPoWGk4UUN3ME21Nk4xQCCwTR?=	NULXeVVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF539	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTV{LkO1JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-2650	NF21[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXFTWM2OD13Mj62PUBvVQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GR-ST	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTV{Lki3JI5O	NV25VIlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
YKG-1	M3jqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGO5Z\|BKSzVyPUWzJI5O	MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MES-1	NFnMe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTV\|LkK2JI5O	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HLE	NWDm[VJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTV\|LkS3JI5O	NUW3UWxuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RVH-421	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jiWGlEPTB;NUOuOlchdk1?	NFTv[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
C32	NILJN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvZeFJKSzVyPUWzMlg{KG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PWUGlEPTB;NUSuNkBvVQ>?	M1nqNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNB75	NF;2[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PIb2lEPTB;NUSuNlYhdk1?	NIeyOms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EM-2	NGLZSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzM[2E4UUN3ME21OE41KG6P	M{LIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RH-1	NW\vdIhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LJ[mlEPTB;NUSuO{BvVQ>?	NGD2WWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NKM-1	M1\mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfyfpdKSzVyPUW0MlgyKG6P	Ml[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2405	NID5c5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTV2Lki4JI5O	MnfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-450	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnvUZdoUUN3ME21OU4yPiCwTR?=	NHfWT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A704	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPmTWM2OD13NT61PUBvVQ>?	NWGxUJVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HAL-01	M{LnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nBbWlEPTB;NUWuPFMhdk1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTV3Lkm5JI5O	Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DOK	M33LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j2UmlEPTB;NU[uNFIhdk1?	M4TydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KY821	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rtbGlEPTB;NU[uNkBvVQ>?	MlSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KGN	NWGxeXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLZV4pKSzVyPUW2MlMzKG6P	M3;5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MC116	NIrPbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTV5Lkigcm0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PANC-08-13	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTV6LkCxJI5O	NEXHNo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KE-37	NYfjOWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT5fHExUUN3ME21PE44PyCwTR?=	M2\2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-410	NH21[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHeybWRKSzVyPUW5MlQ4KG6P	M3rmUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RO82-W-1	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVz3doJ{UUN3ME21PU46KG6P	M3vvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
M14	NGD2bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTZyLkC0JI5O	MlmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GI-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrtd3JIUUN3ME22NE4{KG6P	M1rwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ML-2	NUDFN5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTZyLk[yJI5O	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BFTC-905	MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3sTWM2OD14MD62OUBvVQ>?	MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DMS-273	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{iwWWlEPTB;NkCuPFchdk1?	NFjpRY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	NHvkdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\wTWM2OD14MTDuUS=>	NF32Xm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MSTO-211H	NGfyS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTZ\|LkWxJI5O	MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MEG-01	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknQTWM2OD14Mz61NkBvVQ>?	NIi4SG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
M059J	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTZ\|LkW4JI5O	MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LN-405	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTZ\|Lki1JI5O	NFzOW\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1581	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfqTWM2OD14ND6wN{BvVQ>?	NF;VN4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TCCSUP	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3joc2lEPTB;NkSuOVMhdk1?	NHu1XWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW872	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTZ2LkW3JI5O	M3TCPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-510	M165PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mke2TWM2OD14NT63OUBvVQ>?	NVrvPWlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1792	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPHTWM2OD14Nj6xOUBvVQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW13	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTZ4LkWgcm0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-8	NYXmR2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITxR3FKSzVyPU[2MlUzKG6P	NGWxU4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SCH	NIKydWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\1T2RRUUN3ME22O{4yKG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NEC8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXpVHhKSzVyPU[3MlI1KG6P	MoDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuO-3N1	M2n3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vxdmlEPTB;NkeuN\|Ehdk1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EFM-19	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlriTWM2OD14Nz61JI5O	Mly5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HEC-1	NGryNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfGTWM2OD14Nz61NkBvVQ>?	NEXqb5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
T47D	NIDFUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTZ5Lki3JI5O	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SNU-423	NIezV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzj[npKSzVyPU[3Mlk5KG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
WM-115	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTZ6LkG0JI5O	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CaR-1	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTZ6LkK1JI5O	MoHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KU812	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjOflZKSzVyPU[4MlY6KG6P	M3fzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
AM-38	M1f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;5[GlEPTB;NkmuN\|Ehdk1?	M{XpblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KOSC-2	M13u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDpTWM2OD14OT65O{BvVQ>?	NH75cWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MC-IXC	NHH0O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEO4[4dKSzVyPUewMlA5KG6P	Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SCC-4	M2GyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nUdWlEPTB;N{GuN\|ghdk1?	NGnHfJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Calu-3	M1TuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLSTWM2OD15MT65PEBvVQ>?	NV:4S5R[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RPMI-8866	NEfKeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7iTWM2OD15Mj64NkBvVQ>?	M4fJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OVCAR-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\DTWM2OD15Mz6zOkBvVQ>?	MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\MTWppUUN3ME23N{4{QSCwTR?=	MmK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ATN-1	NInEdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTd\|Lki3JI5O	NWTJNW4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CHP-212	NFPFTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rtO2lEPTB;N{SuPVUhdk1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
C2BBe1	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLjdXNKSzVyPUe1MlA{KG6P	NGXnfJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A498	M4HBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTwe2NiUUN3ME23OU4yPSCwTR?=	NGHqR209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SH-4	NFLReoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTd3LkKxJI5O	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SNU-449	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzEb2dKSzVyPUe1Mlc6KG6P	NWT0cW5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RD	M1qxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnsT\|lKSzVyPUe1Mlg3KG6P	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PANC-03-27	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknjTWM2OD15Nj6yOUBvVQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
S-117	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnexTWM2OD15Nj6yO{BvVQ>?	MlHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELzZ5VKSzVyPUe2Mlc2KG6P	NVXhbXFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LK-2	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTd5LkC1JI5O	NH;vV\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW4fJZkUUN3ME23O{41KG6P	NHy3b5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
647-V	NHf3XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4flZmlEPTB;N{iuNFchdk1?	M4LHVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-134-A	M3i4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrLTWM2OD15OT6wN{BvVQ>?	NYLmb3FSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
5637	NIDl[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;pV2lEPTB;N{muNlMhdk1?	NUDDd2RwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1437	M2TVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\Me2lEPTB;OECuOUBvVQ>?	NULPc4t[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H460	NY\XdFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHEdJdOUUN3ME24NU4zOyCwTR?=	NVO5fmRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BxPC-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:1TWM2OD16MT60OkBvVQ>?	NUmzVFFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAN	NVW3UlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXxfmZKSzVyPUixMlg1KG6P	MmfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KINGS-1	M2TDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33pXGlEPTB;OEKuN\|Ihdk1?	NIHlbog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OCUB-M	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLhTWM2OD16Mj60NUBvVQ>?	NWHzTpp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KALS-1	NWPVZWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTh{LkW0JI5O	M17DZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OCI-AML2	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGm3eYtKSzVyPUiyMlYyKG6P	M1vlO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A253	M1:zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWezNpB1UUN3ME24Nk43PSCwTR?=	M3LIWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LCLC-97TM1	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\hUXgyUUN3ME24Nk45PiCwTR?=	MmXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H520	NV;DXGtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT5RXV3UUN3ME24N{4xPiCwTR?=	M1HvSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
P30-OHK	NH\aPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\YU5ZKSzVyPUizMlUhdk1?	M{HFRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SBC-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFf1W4JKSzVyPUizMlUzKG6P	M4D6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCE-T	M3f6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrEXGVKSzVyPUizMlc1KG6P	NYfJO5lrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
JEG-3	M2LGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jVemlEPTB;OESuNUBvVQ>?	NVHoWpNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KG-1	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ezVGlEPTB;OESuNlQhdk1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MIA-PaCa-2	MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjjeIR2UUN3ME24OE42PCCwTR?=	NHnaTXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-33	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;vTWM2OD16NT6wPEBvVQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
639-V	NXfLfYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrNUolFUUN3ME24OU41OiCwTR?=	M1f4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1048	NGfDS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTh4LkOxJI5O	MnfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1573	M13VWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTTb49kUUN3ME24O{41QCCwTR?=	M3zJclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2228	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTh6LkK2JI5O	M2j3R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB14	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTh6LkOgcm0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SCC-25	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy3RpYyUUN3ME24PU45OiCwTR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A431	NVLrNpN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYmx[2lWUUN3ME24PU46PyCwTR?=	MlvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SN12C	M1nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTlyLk[yJI5O	NWnwd414RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HuCCT1	M1nPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFi0OYpKSzVyPUmwMlc3KG6P	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LS-123	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHj5Nm9KSzVyPUmyMlE5KG6P	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-85-1	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\OSIJZUUN3ME25Nk41QCCwTR?=	NWXjNZprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES6	NH;hb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fHfGlEPTB;OUKuPFMhdk1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H650	NX3WfXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTl2LkC5JI5O	NV3Wb4hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H446	M3Xm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7X[3p[UUN3ME25OU4yOiCwTR?=	NWOzeWZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-13	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUC4bnVRUUN3ME25OU44PSCwTR?=	NVL5cZkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HSC-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvRWJhKSzVyPUm1Mlg6KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U031	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLabWJKSzVyPUm2Mlc{KG6P	MlmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-11	NGD4OHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTl4Lki4JI5O	Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GAK	NYnKS4t4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTl6LkmzJI5O	NX7OO2FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-OV-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1noWGlEPTB;MUCwMlA4KG6P	MoPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OMC-1	NGLCfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFyMD6xPEBvVQ>?	NGHuXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TK10	M37KZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1W0UWlEPTB;MUCwMlIyKG6P	MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EKVX	NWHsVFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fUPWlEPTB;MUCwMlYhdk1?	M2DRSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Detroit562	M1G0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\3eGlEPTB;MUCyMlE4KG6P	NVrzOlVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF268	M2\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rqZ2lEPTB;MUCyMlM1KG6P	Mn3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SNU-387	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFyND6xO{BvVQ>?	M3PLSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-231	NWnQbFV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;PTIV5UUN3ME2xNFUvODZibl2=	NYexXZBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1563	NIrQeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVKxVZNzUUN3ME2xNFUvOThibl2=	NHvLcpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-502MG	NYnuWYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTFyNT63JI5O	M3:0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A2780	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nYXWlEPTB;MUC2MlQ4KG6P	NYTXb4V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
IA-LM	M3nacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{frZWlEPTB;MUC3MlUyKG6P	Mn7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-392MG	M1T4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfsTWM2OD1zMEeuOVQhdk1?	MoHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MS-1	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHGye3FKSzVyPUGwO{44OSCwTR?=	MlX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1990	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFyOD61OEBvVQ>?	MmfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HEL	M3j3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYGwVXRQUUN3ME2xNFkvOjlibl2=	M3v3clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1573	NXLJ[\|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDGO2VTUUN3ME2xNFkvOzFibl2=	NX7sZ3BQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1783	NIHlNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELVNWpKSzVyPUGxNE4zOiCwTR?=	NVfXU5BZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-680N	M2fBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3zTWM2OD1zMUCuO\|Yhdk1?	M3G5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-N87	M1nGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{OzXGlEPTB;MUGxMlA1KG6P	M{C2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-MEL-28	M3;BS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTFzMT61OUBvVQ>?	NH[5R3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BT-20	NVXMbVh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[0TWM2OD1zMUKuNFEhdk1?	NGjJO5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1648	M4GxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFzMzDuUS=>	NFvjOYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
no-11	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPMOoI4UUN3ME2xNVMvOjhibl2=	MlfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MOLT-13	M1nZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmT5TWM2OD1zMUOuOFQhdk1?	M{nWRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2170	M33uWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPRW4xGUUN3ME2xNVQvPTFibl2=	MoDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HTC-C3	M1m3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrxTY9KSzVyPUGxOk45PSCwTR?=	NXTRe4ZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LU-99A	NUfxVZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjKd5FKSzVyPUGxO{4zOSCwTR?=	NWT6XXF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC2998	NY\VUHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFzNz65NkBvVQ>?	NH;TOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB13	NUW0[lRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjGNY1SUUN3ME2xNVcvQTlibl2=	NE\sSI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GT3TKB	NU\peWFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\YTWM2OD1zMUiuNFghdk1?	Mo[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BT-549	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTFzOD65OUBvVQ>?	Ml3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H747	M1yzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2q1XGlEPTB;MUG5MlM1KG6P	MlzpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-1	NIG3SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnYeJhoUUN3ME2xNlAvOiCwTR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB831-BLC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInwRmZKSzVyPUGyNE43OyCwTR?=	NIjydpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NMC-G1	M{LkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DoeWlEPTB;MUKxMlEyKG6P	MnnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-679	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfSTWM2OD1zMkKuNVUhdk1?	NGLncFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HL-60	M4DacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTF{Mz6xJI5O	M{Lx[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MKN7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTF{Mz64N{BvVQ>?	NUT2dJJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RERF-LC-MS	NGXydGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[y[2FKSzVyPUGyOE4{OSCwTR?=	NVLWWWprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DMS-114	NHPyUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDQTWM2OD1zMkWuNFkhdk1?	Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuP-T4	NVfm[nBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDiS4wxUUN3ME2xNlYvQTdibl2=	NGmxcZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC2157	NFmyR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HLWGlEPTB;MUK3MlUhdk1?	M2DIO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SKG-IIIa	M2Xm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF{OD64JI5O	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCT-116	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXW5NIdMUUN3ME2xN\|AvPjRibl2=	NVPsPY05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB30-HNC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXOycZdzUUN3ME2xN\|AvPzhibl2=	M1H6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-270	M2nhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2K2VWlEPTB;MUOwMlg5KG6P	MlLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MFM-223	NX\PeZZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP2TWM2OD1zM{GuOVEhdk1?	M33yS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NH-12	NHu2bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:1e2lEPTB;MUOyMlk6KG6P	NGLZfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
U-118-MG	M{\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfwO45KSzVyPUGzN{43OiCwTR?=	NIPUWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ESS-1	M122fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3joOGlEPTB;MUO1MlE5KG6P	Mlr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-247MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfCZ5FkUUN3ME2xN\|UvOjFibl2=	M4LsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGROV-1	NIeySXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWGyOoRuUUN3ME2xN\|UvPzZibl2=	Mmf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
C-33-A	NIDJSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DPU2lEPTB;MUO1Mlk4KG6P	NHjiW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1693	NWTK[WZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnK5TWM2OD1zM{[uNVIhdk1?	NWHrTpJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MLMA	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLMTWM2OD1zM{[uOVghdk1?	M{TzOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-N-AS	NHP6UXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrKS4FKSzVyPUGzO{4yPyCwTR?=	M4Xoe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1755	NEnS[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr3S2c1UUN3ME2xN\|gvQDVibl2=	M4i3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHP-134	M{nhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj6XpJKSzVyPUGzPU42PSCwTR?=	M1f0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LS-513	NWn3PIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvrSFRKSzVyPUG0NE46OSCyTR?=	NWTmZmNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TE-12	NEHIS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF2MD65N{BvVQ>?	MlvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KNS-42	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTTOZFKSzVyPUG0OE4{KG6P	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SJRH30	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF2ND60OEBvVQ>?	NFOwcHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1092	NIDwcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmK0TWM2OD1zNESuOVIhdk1?	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
H-EMC-SS	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3xTWM2OD1zNE[uPFEhdk1?	MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-3	NHjqW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUCyWW1PUUN3ME2xOFcvPTVibl2=	M2H6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-N-FI	M3:ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XhbmlEPTB;MUS3MlU6KG6P	NFryUlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2126	M1XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXpTpJKSzVyPUG0PE4yPSCwTR?=	NXzC[ZFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1299	NEiyOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlviTWM2OD1zNUCuNlIhdk1?	Ml;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CFPAC-1	M4TYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3UXIdKSzVyPUG1NE43PiCwTR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H661	NF3hVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HUWWlEPTB;MUWxMlI3KG6P	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-70	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rBNWlEPTB;MUWxMlc6KG6P	NVv0eo5IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW900	NGDwRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfYZpFKSzVyPUG1OE43PSCwTR?=	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Ca-Ski	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF3Nj6zPUBvVQ>?	M4Hod\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HPAF-II	NGHwVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVH1WlJWUUN3ME2xOVYvPDdibl2=	NG\ZUpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	M2LTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnG[4ZKSzVyPUG1O{4yKG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LC-2-ad	NUfBe\|l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLxTWM2OD1zNUiuOlIhdk1?	NWfnSIt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC1806	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTF4Nz64PEBvVQ>?	NGn6XZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
UACC-62	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PocWlEPTB;MU[4MlA6KG6P	M2XhSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KM-H2	MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W4c2lEPTB;MUewMlU5KG6P	M{SzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2347	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF5Mj63NkBvVQ>?	M4PlSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SCC-15	NWfLbY96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTF5Mz62OkBvVQ>?	NWL0SGg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB49-HNC	NH;FVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33TXGlEPTB;MUezMlgyKG6P	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GMS-10	NInWN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HuSWlEPTB;MUezMlk1KG6P	NV2xVHEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2052	NIL2eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF5ND65JI5O	NYe2SmZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW626	M3S4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfPTWM2OD1zN{[uNFYhdk1?	NWnhb3dMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MDA-MB-415	M4j6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGL2NnlKSzVyPUG3Ok43OSCwTR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Saos-2	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULiVnY6UUN3ME2xO\|kvOzVibl2=	NIPRO2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DK-MG	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGntWo9KSzVyPUG4NE4{KG6P	M3r4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNU-C2B	M1vydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF6MD63N{BvVQ>?	NXv4V2pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A427	NYPh[oVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\ZTWM2OD1zOEKuOVchdk1?	M3\HRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KP-N-YS	M{Tq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrzTWM2OD1zOEWgcm0>	NULPVIlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
J82	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXN[HBKSzVyPUG4OU4yQCCwTR?=	NUDRT2tbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-411N	NITDPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DI[mlEPTB;MUi3MlI5KG6P	NGjLRZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC1937	M4LocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF6Nz60PUBvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OE33	NHvKcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3S5VWlEPTB;MUi4Mlk4KG6P	NIrpRlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB7	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTF6OT64PUBvVQ>?	M1nt[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW684	NHewdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rjOGlEPTB;MUm2MlE{KG6P	NX\sRldTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-144	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7yRlltUUN3ME2xPVYvOTVibl2=	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-30	NGTWTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3ftOWlEPTB;MUm2MlIhdk1?	NWHhdJh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DBTRG-05MG	M4fGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1v2XmlEPTB;MUm4MlQ4KG6P	NHLacoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1395	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF7OD64OUBvVQ>?	NYnZTIxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2122	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TOfGlEPTB;MkCwMlU6KG6P	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
no-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfmUXo1UUN3ME2yNFEvODRibl2=	MmTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW48	NVTKUIluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\ZTWM2OD1{MEGuN\|Ehdk1?	MoDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1650	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LlUGlEPTB;MkC0MlAyKG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MZ1-PC	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIiwUVdKSzVyPUKwOU42QCCwTR?=	NYe4[5RpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U-266	NWe0UXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHZWZlKSzVyPUKwOU44QSCwTR?=	NXPvR5c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAS-1	M1TKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\BNod{UUN3ME2yNFcvPDRibl2=	Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
AU565	M4HN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLmZYlFUUN3ME2yNVIvQDJibl2=	NHPaN4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
UACC-257	M2HF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJzMz65PUBvVQ>?	NXrvNJlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-27	NEHqW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHlOlBpUUN3ME2yNVcvODVibl2=	MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H23	NHHSTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G1OmlEPTB;MkG5MlM{KG6P	NV7IbmZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TE-6	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXZTWM2OD1{MUmuOlghdk1?	MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TGBC24TKB	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rCWmlEPTB;MkKyMlE4KG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnzTWM2OD1{MkKuPFghdk1?	NIrOc\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RCC10RGB	M1\Me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPvOohKSzVyPUKyOE4yQSCwTR?=	NFHSVFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H596	NFjyRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJ{OD6yNkBvVQ>?	M1y0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW954	NHnsOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ\|Mz64N{BvVQ>?	NXfqeWsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2087	NH7YRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJ\|ND61NUBvVQ>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	NHXWcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfZN2RKSzVyPUKzOU4yQSCwTR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KM12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXMXFBKSzVyPUKzOU44KG6P	MojPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BT-474	NEnDPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTJ\|NT63N{BvVQ>?	NGnET5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
IST-MES1	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nmZmlEPTB;MkO2MlU4KG6P	NV;6WYlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-1197	NInBR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPQTWM2OD1{M{iuNFkhdk1?	M4OzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-54	Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkX5TWM2OD1{M{iuOFkhdk1?	M3znd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB10	M4L4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ2MD6wOkBvVQ>?	NGrnXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PANC-10-05	NFrjO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTJ2NT61OkBvVQ>?	M4nafFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H522	NVO0SJRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfETWM2OD1{NEiuN\|Ehdk1?	MonWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A388	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDIRXJKSzVyPUK0PU45OiCwTR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GOTO	NIjsRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HGTWlEPTB;MkWwMlI6KG6P	NEfMeGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KLE	M37QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLyeotKSzVyPUK1NU45PyCwTR?=	M3GxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-520	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTWTpJMUUN3ME2yOVIvQDZibl2=	NVrSPYxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCE-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJ4Mj61JI5O	NE\nNVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KURAMOCHI	M{Cwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJ4NT65JI5O	NFLs[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC38	NICzSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJ4Nj60PEBvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
FADU	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL4TWM2OD1{Nk[uOlMhdk1?	NYPMR\|ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CW-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHH0cGpKSzVyPUK2PU46PiCwTR?=	NVHDeVhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
L-428	NEnESYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nkfmlEPTB;Mke1MlE2KG6P	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCC1569	M3PzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LjemlEPTB;Mke1Mlg1KG6P	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H810	NF\XU\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHJZo9KSzVyPUK3PE4{OSCwTR?=	M4DHNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB771-HNC	NUnWNJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D2cmlEPTB;Mki1Mlg1KG6P	M4T6U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LCLC-103H	NWDPb5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXKybotrUUN3ME2yPFUvQTlibl2=	NFjhWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EFO-21	NH\ZO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTJ6Nz62PEBvVQ>?	NHXzVZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-72	M4TMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTXTWM2OD1{OUOuNVkhdk1?	NUnteWFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SCC-9	NUS1cIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rY[mlEPTB;MkmzMlIzKG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COLO-829	M{HmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;sTWM2OD1{OU[uOUBvVQ>?	NVTLTFQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U-87-MG	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3pOGxCUUN3ME2zNFAvPzNibl2=	M{HkdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MZ7-mel	NWHCcm1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnL3TWM2OD1\|MkOuO\|Yhdk1?	NEXOSHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1770	NYDYOmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7MTWM2OD1\|Mk[uO\|Qhdk1?	NITUSY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\pc3ZPUUN3ME2zNlgvOSCwTR?=	Mm[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SiHa	NInVWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX2TWM2OD1\|MkmuNlQhdk1?	NIjXZ4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	NIjLXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTN\|Nj63O{BvVQ>?	M1;LTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DJM-1	NYXXW\|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV65T\|IxUUN3ME2zOFAvOzNibl2=	NGLCUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OE19	NH3aR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXqV\|JKSzVyPUO0NE42OyCwTR?=	NXnVPIJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1651	NHvKNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LDd2lEPTB;M{S0MlE5KG6P	NVrWbnozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-792	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PG[2lEPTB;M{W0MlQzKG6P	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ACHN	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN3Nj63NUBvVQ>?	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TH-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3sPJVKSzVyPUO3PU46PSCwTR?=	M{jiUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HT-1376	M2PWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3hTWM2OD1\|OESuPFghdk1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RH-18	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C1VmlEPTB;M{m0Mlc1KG6P	M2TlTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB6	M2Tydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHXTWM2OD1\|OU[uOlYhdk1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	NGP4XI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:0TWM2OD12MEOuN\|chdk1?	MmXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
UACC-893	NH3qNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTJe2pCUUN3ME20NFYvPDdibl2=	MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DSH1	M1HqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTRyNj65NUBvVQ>?	NGL4fGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-10	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HhR2lEPTB;NEC3MlAyKG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCC70	M1\VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPlUZB3UUN3ME20NFkvOjFibl2=	MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TGBC11TKB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfSOGZ6UUN3ME20NVAvOzNibl2=	NYfRcGlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H727	NHvw[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVX3O3ZLUUN3ME20NVIvOTFibl2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ALL-PO	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTRzNT62PUBvVQ>?	M4nL[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ABC-1	M4DN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLUTWM2OD12MkCuOFUhdk1?	M1Tib\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H69	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;xTWM2OD12Mk[uO\|Yhdk1?	MmDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GP5d	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;5UotpUUN3ME20N\|QvPDFibl2=	NVLPfpVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
UMC-11	NF\jeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NViyNJJYUUN3ME20OVgvOzZibl2=	M4jOSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RMG-I	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfI[GxKSzVyPUS2O{42PiCwTR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
YAPC	NWHrenpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXkTWM2OD12OUCuOkBvVQ>?	NYKyN2h1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-1034	NVLaSHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTR7MT6wOkBvVQ>?	NHjaZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RCM-1	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnYTWM2OD12OU[uOlghdk1?	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1954	NGnaOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PhNGlEPTB;NUGyMlUhdk1?	NUfMZlhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MEL-24	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzHeWtKSzVyPUWxOk42OSCwTR?=	MnLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB12	NUTCdWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn6R4xbUUN3ME21NlgvPDJibl2=	MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW756	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTV3ND65OkBvVQ>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCC1187	NWTaTXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nSS2lEPTB;NUe1Mlg{KG6P	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2342	NFXLWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoG4TWM2OD13OUCuN\|khdk1?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2291	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSzeo1rUUN3ME21PVgvOzFibl2=	NVnCdFFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OVCAR-3	M{X5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHZTWM2OD13OUiuPVYhdk1?	NH65UYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MHH-NB-11	NE[2bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPS[2xiUUN3ME22NlkvODFibl2=	NHrwUoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SAS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37EdmlEPTB;NkWyMlY4KG6P	M{\ObVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COLO-824	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnTbHhKSzVyPU[4PU4{PyCwTR?=	NXnBVoF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC1395	M3PCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7ucVlKSzVyPU[5PE42KG6P	MnvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-668	NIW3[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHaTWM2OD15ME[uNUBvVQ>?	MkXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H226	NYL5NWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3QfXVKSzVyPUewO{45KG6P	MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB17	M3;PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlWzTWM2OD15MkGuO\|Uhdk1?	NIHBeWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW1463	NVPPcJNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rZNGlEPTB;N{O5MlE6KG6P	NXfGVZJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TGW	NELOdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHyUWZKSzVyPUe2NE4yPSCwTR?=	MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H526	M2m3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTh{Mz61N{BvVQ>?	M3vjN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COR-L88	M3qyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH2wfIlKSzVyPUi0PE4yOiCwTR?=	M2H1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H441	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Ple2lEPTB;OEm1MlIzKG6P	NXHqfm04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H630	NF;wUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\JTWM2OD17MUKuPVYhdk1?	NGT2emM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Mo-T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv3TWM2OD17NEeuPFghdk1?	MlfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
JAR	NGD3XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnGfGhKSzVyPUm1Ok4zPCCwTR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1838	NH:wWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW3OoxKUUN3ME2xMlAzOzh6IN88US=>	NELZTGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DoTc2-4510	NY\tN\|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfQcFNKSzVyPUGuNFc{PzZizszN	MmnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MKN28	NHrPS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DY[GlEPTB;MT6wPVAzPCEQvF2=	NWr6dJVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HuP-T3	NEPmcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfzTWM2OD1zLkGxPVA2KM7:TR?=	NUTsWGhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TE-9	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPFZWNKSzVyPUGuNVI6PzNizszN	NVfNfGliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NY	NYTx[2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwMU[3PVIh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HT55	M2HLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPPSWhKSzVyPUGuN\|E{PDRizszN	M1rGWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW837	M3HyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTWTWM2OD1zLkOyPVc5KM7:TR?=	M2\rXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2029	NEnVdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTHNVJoUUN3ME2xMlQyPzlzIN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IST-SL1	NFS2eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnBOYs6UUN3ME2xMlQ1OjRizszN	NYj0d\|NwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-741	M3LjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfNNpdDUUN3ME2xMlQ6PzdzIN88US=>	M1XIS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-65	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwNkKyOFkh\|ryP	M4jxN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1304	MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j2N2lEPTB;MT62OVQ6QCEQvF2=	NYixcFBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KARPAS-299	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULrT2g3UUN3ME2xMlc6PDd7IN88US=>	M2r0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H358	M{CyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmizTWM2OD1zLkm1OVA{KM7:TR?=	NH7XVJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OAW-28	NUPNfHNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[4fJNDUUN3ME2yMlA3QTF7IN88US=>	M1zrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C8166	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjsXnQyUUN3ME2yMlY{Ozl{IN88US=>	MoPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-678	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;JW2lEPTB;Mj64N\|c3QCEQvF2=	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-N-DZ	NYHxVVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTJwOE[zPFEh\|ryP	NH\wdJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H82	MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm2fWl5UUN3ME2yMlkxOzZ7IN88US=>	NYnrdY1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
JVM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnTeIlKSzVyPUOuNFMyQDhizszN	M1nM[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1116	NID1fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle3TWM2OD1\|LkC1OFEyKM7:TR?=	M2TpOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-453	NWLZdVlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\MZWlEPTB;Mz6xNFQ{QSEQvF2=	M3LYSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Calu-6	NFLQ[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTNwMUm5O{DPxE1?	NXXnOppwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SHP-77	M1\kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;yTWM2OD1\|LkWyPEDPxE1?	NXzhRmRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Capan-2	M3HqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrpTWM2OD12LkOyOVgyKM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW948	NGTKc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HEeGlEPTB;ND63OFc4QSEQvF2=	NFvHZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HDLM-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLuTWM2OD13LkC3O\|I2KM7:TR?=	NVPte5J7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LAN-6	NUTac5p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTY[5BRUUN3ME22MlIyPDl3IN88US=>	NI\lblA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LU-135	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTZwNEOwO\|ch\|ryP	NF;4bG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
T84	M2jCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLYd49KSzVyPU[uPVg3PCEQvF2=	MkDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAPAN-1	NYD0Um1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3POPWlEPTB;Nz62NlI{OyEQvF2=	NUHFVGlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1417	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;pOGlEPTB;Nz65NVc{OSEQvF2=	M3m3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BALL-1	NXGwRmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRThwNUC0NFkh\|ryP	NX25[2tyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-29	M2rU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvOTWM2OD17LkC3OVk6KM7:TR?=	M{e5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C3A	NXq5bmtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT3ZWFKSzVyPUmuPFg{QTRizszN	MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1993	M2nKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjxPWtKSzVyPUGwMlUxQDFizszN	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-1	NXz0b4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHm2d3hKSzVyPUGxMlYzQDlizszN	NEjJeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DU-145	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i3dmlEPTB;MUSuOVA2OiEQvF2=	MnP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KP-N-YN	NYfqc4FjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1WzWWlEPTB;MUSuOVExOyEQvF2=	NGTFb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CCRF-CEM	NEfUdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTF2Lke4NFkh\|ryP	NFP4OIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ZR-75-30	NGjXVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\1TWM2OD1zNj6zN\|A{KM7:TR?=	M2jMU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A673	NGW0VYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LEWGlEPTB;MkCuOVUxPyEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
K-562	NU\IRVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ6LkSxPFMh\|ryP	Ml7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BEZ235
Smiles	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1
NCT01337765	Completed	Drug: BEZ235 + MEK162	Unspecified Adult Solid Tumor Protocol Specific\|Solid Tumor	Pfizer	July 8 2011	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)